MOTS-c dosage: what has been published
Subcutaneous and intramuscular injection: the routes the 2026 HHS policy lists.
There is no published human dose for MOTS-c. Mouse studies injected it into the abdominal cavity, a route the policy does not list, and those doses cannot be converted for people. MOTS-c is not FDA-approved, and REMEVi does not currently offer it. Published protocols vary; a licensed provider sets your dose; never self-dose.
MOTS-c is not FDA-approved. Since HHS’s October 2026 interim policy, a state-licensed 503A pharmacy may compound it on a patient-specific prescription under listed conditions.
REMEVi does not currently offer MOTS-c.
Published MOTS-c doses by route
| Route | Published amount and frequency | Who was studied | Source |
|---|---|---|---|
| Subcutaneous, MOTS-c | No published human dose found (checked 2026-11-02) | — | PubMed search; USADA |
| Intramuscular, MOTS-c | No published human dose found (checked 2026-11-02) | — | PubMed search; USADA |
| Subcutaneous, CB4211 (an analog, not MOTS-c) | 25 mg once daily for 4 weeks | 20 adults with obesity and fatty liver, 11 on drug and 9 on placebo; company-reported | CohBar press release, 2021 |
The CB4211 row is a different molecule and is not a MOTS-c dose. It is listed because it is the closest published human injection data. Published protocols vary; a licensed provider sets your dose; never self-dose.
Animal doses, and why they are not human doses
The main MOTS-c mouse studies gave it by intraperitoneal injection (into the abdominal cavity), which is not a route the policy covers. As published, in mice:
- Lee et al., 2015: 0.5 mg/kg per day for 3 to 8 weeks, and 5 mg/kg per day for 7 days.
- Reynolds et al., 2021: 5 or 15 mg/kg per day for up to 2 weeks; in a late-life group, 15 mg/kg three times a week after 8 weeks of daily dosing.
Mouse doses per kilogram do not convert to a human dose by simple arithmetic, and we do not convert them.
Why published MOTS-c dosage charts differ
- No human dose of MOTS-c itself has been published, so charts are extrapolated from mice or passed between sellers.
- Some charts borrow the CB4211 trial dose, though CB4211 is a different molecule.
- Mouse studies used intraperitoneal injection; human charts list subcutaneous or intramuscular, which absorb differently.
- Vial strengths and mixing volumes vary from product to product, so the same “dose” can mean different amounts.
Reconstitution basics
A compounded MOTS-c prescription comes from a 503A pharmacy, labeled for you. Follow the pharmacy label and your prescriber’s instructions on whether and how to mix it. General basics:
- If the product is a powder, mix it with the diluent the pharmacy specifies, nothing else.
- Wipe the vial stopper with alcohol and use a new sterile syringe every time; never share one.
- Store the vial exactly as the label says and discard it by the date on the label.
- Under the policy, no device other than an FDA 510(k)-cleared syringe may be packaged with the drug.
- Put used needles in a sharps container.
More questions
What is the MOTS-c dosage?
There is no published human dose for MOTS-c. Mouse studies injected it into the abdominal cavity, a route the policy does not list, and those doses cannot be converted for people. MOTS-c is not FDA-approved, and REMEVi does not currently offer it. Published protocols vary; a licensed provider sets your dose; never self-dose.
Sources
- Lee et al., Cell Metabolism 2015 — The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance (read November 2, 2026)
- Reynolds et al., Nature Communications 2021 — MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis (read November 2, 2026)
- CohBar press release (via BioSpace), Aug 10, 2021 — Positive topline results from the Phase 1a/1b study of CB4211, an analog of MOTS-c (company-reported, not peer-reviewed) (read November 2, 2026)
- USADA — What is the MOTS-c peptide? (read November 2, 2026)
- HHS, Federal Register — Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (91 FR 68526, October 30, 2026) (read November 2, 2026)
- Holtz, Beaver & Rosen (Foley & Lardner), National Law Review, Oct 30, 2026 — HHS Announces Limited Enforcement Discretion for Compounding of Six Peptides (read November 2, 2026)
- Bigica, Nutritional Outlook, Nov 2, 2026 — What the Interim Compounding Pathway for Peptides Could Mean for Supplement Brands (read November 2, 2026)
Medically reviewed by Linda West-Conforti, RN · CA RN #389453 ·